American Portfolios Advisors’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

American Portfolios Advisors’s Portfolio GERM Stock Details GERM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$174K	Sell	8,403 -1,755	-17%	-$42.7K	0.01%	1070
2022 Q2	$236K	Sell	10,158 -1,326	-12%	-$31.6K	0.01%	965
2022 Q1	$314K	Sell	11,484 -779	-6%	-$21.9K	0.01%	951
2021 Q4	$437K	Hold	12,263	–	–	0.01%	799
2021 Q3	$503K	Sell	12,263 -554	-4%	-$23.4K	0.02%	708
2021 Q2	$513K	Buy	12,817 +1	+0%	+$37	0.02%	696
2021 Q1	$455K	Buy	12,816 +40	+0.3%	+$1.5K	0.02%	691
2020 Q4	$397K	Buy	12,776 +9,561	+297%	+$291K	0.02%	632
2020 Q3	$88.9K	Buy	+3,215	New	+$94.5K	0.01%	1099

Other funds holding GERM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

American Portfolios Advisors's GERM Position: Q3 2022 in Review

American Portfolios Advisors reduced its Amplify Treatments, Testing and Advancements ETF (GERM) stake by 17% in Q3 2022, selling an estimated $42.7K and leaving 8,403 shares worth $174K. The position accounts for 0.01% of the portfolio, ranked #1070.

American Portfolios Advisors first reported a position in GERM in Q3 2020 and has held it in 9 quarters since. The position peaked at $513K in Q2 2021. 22 funds tracked by Wall St. Rank hold GERM as of Q3 2022.

American Portfolios Advisors held 8,403 shares of Amplify Treatments, Testing and Advancements ETF worth $174K as of Q3 2022.
American Portfolios Advisors sold 1,755 Amplify Treatments, Testing and Advancements ETF shares in Q3 2022, an estimated $42.7K.
Amplify Treatments, Testing and Advancements ETF made up 0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #1070 holding.
American Portfolios Advisors first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and has held it in 9 quarters since.
American Portfolios Advisors's Amplify Treatments, Testing and Advancements ETF position peaked at $513K in Q2 2021.
22 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.